Health Condition 1: null- EPILEPSY PATIENTS
Conditions
Interventions
None listed
Sponsors
Self
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed drug naive epileptic patients aged between 18-60 years of age of either gender Patients who will be initiated on monotherapy with phenytoin or levetiracetam or oxcarbazepine Patients who are willing to give informed consent
Exclusion criteria
Exclusion criteria: Patients with history of psychiatric or progressive neurological disorders Patients with history of other co morbid conditions like ischemic heart disease kidney disease liver disease thyroid disorders and other endocrinopathies Patients with history of diseases that could influence the level of oxidative stress such as diabetes mellitus arterial hypertension malignancies recent surgery and trauma Patients on drugs that influence the level of oxidative stress such as vitamins herbal medicines for the last 3 months Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in oxidative parameters (MDA NO and GSH) compared from baseline to the end of the study Timepoint: Baseline after 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in seizure frequency from baseline to three months after treatment in adult epileptic patientsTimepoint: baseline after 3 months | — |
Countries
India
Contacts
Public ContactB SWATHI
Nizams Institute of Medical Sciences
Outcome results
None listed